To assess the in vivo action of anti-EGFR antibody on the lung lesions caused by LAM/TSC cell administration, anti-EGFR antibody were i.p. administered 26 weeks after cell inhalation twice weekly for 4 weeks and then the mice were sacrificed. This evidence concerns the gene EGFR and tuberous sclerosis.